NASDAQ:GPCR Structure Therapeutics (GPCR) Stock Price, News & Analysis $39.41 +0.59 (+1.52%) (As of 10/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Structure Therapeutics Stock (NASDAQ:GPCR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$37.89▼$39.6250-Day Range$34.42▼$44.0252-Week Range$26.61▼$75.02Volume341,105 shsAverage Volume782,556 shsMarket Capitalization$1.84 billionP/E RatioN/ADividend YieldN/APrice Target$87.83Consensus RatingBuy Company OverviewStructure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Read More… Download for free: Tesla investment guide (Ad)This doesn’t happen often… But our resident Tesla trading expert has just published a brand new e-book outlining his bullish case for Tesla. And he’s currently giving away digital copies for free.claim your free digital copy today, simply follow this link and enter your email address. Structure Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks53rd Percentile Overall ScoreGPCR MarketRank™: Structure Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 593rd out of 998 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingStructure Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageStructure Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Structure Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Structure Therapeutics are expected to grow in the coming year, from ($0.79) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Structure Therapeutics is -52.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Structure Therapeutics is -52.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStructure Therapeutics has a P/B Ratio of 4.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Structure Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.26% of the float of Structure Therapeutics has been sold short.Short Interest Ratio / Days to CoverStructure Therapeutics has a short interest ratio ("days to cover") of 14.1, which indicates bearish sentiment.Change versus previous monthShort interest in Structure Therapeutics has recently decreased by 0.09%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldStructure Therapeutics does not currently pay a dividend.Dividend GrowthStructure Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.26% of the float of Structure Therapeutics has been sold short.Short Interest Ratio / Days to CoverStructure Therapeutics has a short interest ratio ("days to cover") of 14.1, which indicates bearish sentiment.Change versus previous monthShort interest in Structure Therapeutics has recently decreased by 0.09%, indicating that investor sentiment is improving. News and Social Media3.7 / 5News Sentiment0.69 News SentimentStructure Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Structure Therapeutics this week, compared to 4 articles on an average week.Search Interest10 people have searched for GPCR on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows5 people have added Structure Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Structure Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.43% of the stock of Structure Therapeutics is held by insiders.Percentage Held by Institutions91.78% of the stock of Structure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Structure Therapeutics' insider trading history. GPCR Stock News HeadlinesCan Roche Challenge Lilly and Novo in the Weight Loss Market? (GPCR)One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate.October 22 at 10:54 AM | marketbeat.comNovo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges (GPCR)Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now?September 24, 2024 | marketbeat.comDownload for free: Tesla investment guideThis doesn’t happen often… But our resident Tesla trading expert has just published a brand new e-book outlining his bullish case for Tesla. And he’s currently giving away digital copies for free.October 23, 2024 | WealthPress (Ad)Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity PatientsOctober 22 at 8:33 PM | seekingalpha.comEvan Seigerman’s Buy Rating Highlights Structure Therapeutics’ Innovative Approach in Obesity Treatment MarketOctober 22 at 5:29 AM | markets.businessinsider.comConsumer, labor groups urge FTC to block Catalent sale to Novo Holdings - reportOctober 17, 2024 | seekingalpha.comStructure Therapeutics (GPCR): Innovating Oral Therapies for Obesity and DiabetesOctober 16, 2024 | msn.comIs Structure Therapeutics Inc. (GPCR) the Best Young Stock To Buy Now?September 29, 2024 | msn.comSee More Headlines GPCR Stock Analysis - Frequently Asked Questions How have GPCR shares performed this year? Structure Therapeutics' stock was trading at $40.76 at the start of the year. Since then, GPCR stock has decreased by 3.3% and is now trading at $39.41. View the best growth stocks for 2024 here. How were Structure Therapeutics' earnings last quarter? Structure Therapeutics Inc. (NASDAQ:GPCR) released its quarterly earnings results on Thursday, August, 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. When did Structure Therapeutics IPO? Structure Therapeutics (GPCR) raised $150 million in an initial public offering (IPO) on Friday, February 3rd 2023. The company issued 10,740,000 shares at $13.00-$15.00 per share. Who are Structure Therapeutics' major shareholders? Structure Therapeutics' top institutional investors include Exchange Traded Concepts LLC (0.09%), Griffin Asset Management Inc. (0.03%), SG Americas Securities LLC (0.02%) and Bank Pictet & Cie Europe AG (0.01%). How do I buy shares of Structure Therapeutics? Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Structure Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Structure Therapeutics investors own include Alamos Gold (AGI), Plug Power (PLUG), KALA BIO (KALA), Ovid Therapeutics (OVID), Comtech Telecommunications (CMTL), Fortress Biotech (FBIO) and Alto Ingredients (ALTO). Company Calendar Last Earnings8/08/2024Today10/22/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GPCR CUSIPN/A CIK1888886 Webwww.structuretx.com Phone628-229-9277FaxN/AEmployees136Year FoundedN/APrice Target and Rating Average Stock Price Target$87.83 High Stock Price Target$118.00 Low Stock Price Target$65.00 Potential Upside/Downside+122.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,620,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.12% Return on Assets-19.11% Debt Debt-to-Equity RatioN/A Current Ratio41.38 Quick Ratio41.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.77 per share Price / Book4.03Miscellaneous Outstanding Shares46,619,000Free Float51,803,000Market Cap$1.84 billion OptionableOptionable Beta-3.53 This page (NASDAQ:GPCR) was last updated on 10/23/2024 by MarketBeat.com Staff From Our Partners$20 = Ounce of Gold?I've discovered a way to get exposure to MORE than an ounce of gold... for under $20. It's not bullion. It'...Monument Traders Alliance | SponsoredDon’t Miss Out: Elon’s Game-Changing InventionThis is Elon Musk's latest AI innovation… According to Eric Fry, a seasoned expert with 30 years of experie...InvestorPlace | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored[INSIDE] The $16 “AI stock” set to soarThere's one tiny firm that's providing the backbone of the entire AI sector. It's at the heart of $85 trill...Behind the Markets | SponsoredElection rigged? We caught them red-handed…What happens if NOBODY will be elected the next President of the United States on Nov. 5? Not Donald Trump...Banyan Hill Publishing | SponsoredIt’s delivered 859% in 2.5 months…We’ve gotten a lot of messages asking… what should we buy if Trump wins? What should we buy if Kamala wins?...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Structure Therapeutics Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.